Nivolumab Beats Chemotherapy as Second-Line Treatment for Advanced Melanoma

September 30, 2014 5:48 AM

13 0

Treatment with nivolumab (Opdivo) demonstrated superior objective response rates (ORR) and longer durations of response compared with chemotherapy in a phase III trial of patients with previously treated advanced metastatic melanoma, reported Jeffrey Weber, MD, at the 2014 ESMO Congress.

Nivolumab is a fully human IgG4 PD-1 immune checkpoint inhibitor antibody with durable antitumor activity. Patients in the trial were previously treated with anti-CTLA-4 therapy with ipilimumab and a BRAF inhibitor, if they were positive for a BRAF mutation. In phase I trials of pretreated patients ...

Read more

To category page